` MNPR (Monopar Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

MNPR
vs
S&P 500

Over the past 12 months, MNPR has significantly outperformed S&P 500, delivering a return of +145% compared to the S&P 500's +12% growth.

Stocks Performance
MNPR vs S&P 500

Loading
MNPR
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MNPR vs S&P 500

Loading
MNPR
S&P 500
Difference
www.alphaspread.com

Performance By Year
MNPR vs S&P 500

Loading
MNPR
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Monopar Therapeutics Inc vs Peers

S&P 500
MNPR
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Monopar Therapeutics Inc
Glance View

Market Cap
500.5m USD
Industry
Biotechnology

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.

MNPR Intrinsic Value
Not Available
Back to Top